Answer
Oct 17, 2025 - 04:44 AM
In Phase 2 clinical trials, bimagrumab demonstrated significant increases in skeletal muscle mass and reductions in body fat in patients with obesity and type 2 diabetes. However, while body composition improved, the trials did not show significant improvements in glycemic control compared to placebo. As a result, further development for obesity and diabetes indications was discontinued.
